News | May 08, 2009

FDA Clears Siemens' New Biograph TruePoint 16-Slice PET/CT System

May 8, 2009 – Siemens Healthcare announces FDA 510(k) clearance for the new Biograph TruePoint 16-slice PET/CT system, which is now commercially available.
With the latest addition to the Biograph TruePoint PET/CT family, Siemens is making PET/CT technology accessible to all facilities. It features high-performance capabilities, such as High-Definition PET and routine 10-minute, whole-body imaging. In addition, the Biograph TruePoint 16 is able to provide 2 mm uniform PET resolution throughout the field of view and a two-time improvement in signal-to-noise ratio, which is designed to enable small lesion detection. The system is also available with Siemens TrueV extended PET field of view technology, which enables clinicians to perform imaging studies at twice the scan speed or half the patient dose.
The new Biograph 16-slice PET/CT system is built for patient comfort and features a 500-pound (227 kg) capacity patient bed, a 70-centimeter patient bore and efficient workflow system. The system is also mobile-ready, equipped to maximize on-location patient throughput with fast, 10-minute imaging.
The Biograph TruePoint 16-slice PET/CT system has been FDA-cleared under the name Siemens Medical Solutions USA Inc.
For more information: www.siemens.com/healthcare

 

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init